SMARCB1 and sarcoma: Besides targeting the genomic alteration, epigenetic regulators such as DNA methylation, histone modification and microRNA are emerging potential targets against sarcomas including tazemetostat, an EZH2 inhibitor for epithelioid sarcoma with loss of SMARCB1/INI1/BAF47 as mentioned above.